Latest odronextamab data in relapsed/refractory follicular lymphoma showed compelling responses and overall maintenance of patient-reported outcomes

Updated results presented at ash demonstrated an 80% objective response rate and a 73% complete response (cr), with a 23-month median duration of response and 24-month median duration of cr

REGN Ratings Summary

REGN Quant Ranking